This is great news to hear. The consistency of data coming from multiple unrelated researchers really strengthens the case for paxalisib to not only become the next standard of care, but to remain as a core part of any future combination therapy for such cancer patients. Very encouraging both from the standpoint of cancer patients as well as from the standpoint of a Kazia investor.
KZA Price at posting:
$1.36 Sentiment: Buy Disclosure: Held